S. 5316, National Security Investment Screening. Quorum's AI analysis reads it as a trade-off: gains for some, costs for others.
S. 5316 · Mixed
What it does
This bill expands the Defense Production Act to treat biotechnology (pharmaceuticals, biologics, drug discovery, clinical research) as a 'prohibited' or 'notifiable' technology for purposes of outbound investment screening. It requires the Treasury and State Departments to issue rules within one year defining which biotech transactions to China require government approval or notification, with particular focus on licensing deals, joint ventures, and equity investments that transfer drug-development know-how or manufacturing capability to Chinese firms. The stated purpose is to prevent U.S.
The analysis names U.S. pharmaceutical and biotech companies (reduced competition from Chinese firms, potential price-s — and 1 more group — among the beneficiaries.
The trade-off
The bill delegates core definitional authority to the Treasury/State Departments via rulemaking, leaving the scope of 'prohibited' and 'notifiable' biotech transactions undefined until after enactment. This creates regulatory uncertainty for U.S. biotech companies and investors, potentially chilling legitimate partnerships and licensing deals with non-Chinese foreign entities if rules are written
The analysis put a high warning level on this bill. Transparency scores 65%, and the analysis found no provisions unrelated to the bill's subject.
Who is behind it
Filed by Pete Ricketts. Cosponsored by Elissa Slotkin.